Skip to main
BLCO
BLCO logo

BLCO Stock Forecast & Price Target

BLCO Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 8%
Buy 25%
Hold 58%
Sell 8%
Strong Sell 0%

Bulls say

Bausch & Lomb has raised its 2025 revenue guidance to between $5,050 million and $5,150 million, indicating anticipated constant currency growth of 5-7%, with adjusted EBITDA projected to reach between $860 million and $910 million. The company has reported a robust 6% revenue growth on a constant currency basis, positively influenced by foreign exchange gains and significant growth in prescription sales for MIEBO and XIIDRA. Additionally, the regained momentum in premium intraocular lenses highlights Bausch & Lomb's competitive strengths in key market segments, reinforcing a favorable outlook for sustained financial performance.

Bears say

Bausch & Lomb's stock outlook is negatively impacted by several fundamental challenges including pricing pressure on key products like XIIDRA, which could constrain revenue growth and profitability. The company's limited product pipeline and high leverage, stemming from the acquisition of Xiidra, coupled with macroeconomic uncertainties surrounding consumer spending and elective procedures, pose additional risks to its financial stability. Furthermore, ongoing concerns regarding its separation from parent company Bausch Health and potential market volatility from private equity rumors further contribute to the negative sentiment surrounding Bausch & Lomb's stock performance.

BLCO has been analyzed by 12 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 25% recommend Buy, 58% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch + Lomb Corp (BLCO) Forecast

Analysts have given BLCO a Hold based on their latest research and market trends.

According to 12 analysts, BLCO has a Hold consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch + Lomb Corp (BLCO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.